The Food and Drug Administration (FDA) has approved Pfizer’s vaccine, Abrysvo, which protects adults 60 and older from the respiratory syncytial virus (RSV), Pfizer announced on Wednesday.
The approval makes Abrysvo the second RSV vaccine available for the common virus. On May 3, the agency approved GSK’s Arexvy, the world’s first RSV vaccine for adults 60 and older.
“This past RSV season demonstrated the serious consequences and potential health risks this virus poses for older adults,” said Dr. Edward E. Walsh, professor of medicine at the University of Rochester Medical Center and principal investigator in the RENOIR study.
“[The] FDA approval of Abrysvo recognizes significant scientific progress, and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease.”…